{"id":3627,"date":"2023-09-04T15:41:59","date_gmt":"2023-09-04T10:11:59","guid":{"rendered":"https:\/\/gwcindia.in\/blog\/\/?p=3627"},"modified":"2024-08-26T12:35:56","modified_gmt":"2024-08-26T07:05:56","slug":"ipo-jupiter-life-line-hospitals-limited","status":"publish","type":"post","link":"https:\/\/www.gwcindia.in\/blog\/ipo-jupiter-life-line-hospitals-limited\/","title":{"rendered":"IPO : Jupiter Life Line Hospitals Limited"},"content":{"rendered":"

Jupiter Life Line Hospitals Limited IPO<\/h1>\n

Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India.<\/p>\n

Jupiter Life Line Hospitals has been operating as a corporate quaternary care healthcare service provider in the western regions of India and currently operates three hospitals under the “Jupiter” brand in Thane, Pune, and Indore, with a total operational bed capacity of 1194 beds, and 1,306 doctors including specialists, physicians, and surgeons, as of March 31, 2023. The company is currently developing a multi-specialty hospital in Dombivli, Maharashtra, which is designed to accommodate over 500 beds and has commenced construction in April 2023.<\/p>\n\n\n\n\n\n\n\n\n\n
\u00a0SYMBOL<\/strong><\/td>\nJLHL<\/strong><\/td>\n<\/tr>\n
\u00a0ISSUE TYPE<\/strong><\/td>\nBook Built Issue IPO<\/strong><\/td>\n<\/tr>\n
\u00a0ISSUE OPENS ON<\/strong><\/td>\nSeptember 06, 2023 (Wednesday)<\/strong><\/td>\n<\/tr>\n
\u00a0ISSUE CLOSES ON<\/strong><\/td>\nSeptember 08, 2023 (Friday)<\/strong><\/td>\n<\/tr>\n
\u00a0ISSUE PRICE<\/strong><\/td>\nRs.695 To Rs.735 per share<\/strong><\/td>\n<\/tr>\n
\u00a0ISSUE SIZE<\/strong><\/td>\nUp to Rs.869.08 Crores<\/strong><\/td>\n<\/tr>\n
\u00a0FACE VALUE<\/strong><\/td>\nRs.10 per share<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

According to the CRISIL Report, the company’s Thane and Indore hospitals are amongst the few hospitals in the western region of India to provide neuro-rehabilitation services through a dedicated robotic and computer-assisted neuro-rehabilitation center. Additionally, it operates one of the few multi-organ transplant centers in Thane. All the hospitals in Thane, Pune, and Indore have been certified by the National Accreditation Board for Hospitals & Healthcare Providers (NABH) and have been accredited in the field of medical testing by the National Accreditation Board for Testing and Calibration Laboratories (NABL).<\/p>\n\n\n\n\n\n\n\n\n
\u00a0MINIMUM BID<\/strong><\/td>\n20 shares<\/strong><\/td>\n<\/tr>\n
\u00a0MINIMUM AMOUNT\u00a0<\/strong><\/td>\nRs.14,700<\/strong><\/td>\n<\/tr>\n
\u00a0MAXIMUM BID<\/strong><\/td>\n260 shares<\/strong><\/td>\n<\/tr>\n
\u00a0MAXIMUM AMOUNT\u00a0<\/strong><\/td>\nRs.1,91,100<\/strong><\/td>\n<\/tr>\n
\u00a0LISTING DATE<\/strong><\/td>\nSeptember 18,2023 (Monday)<\/strong><\/td>\n<\/tr>\n
\u00a0LISTING AT<\/strong><\/td>\nNSE-BSE<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The company’s inpatient and outpatient revenue is diversified across hospitals with Thane, Pune, and Indore hospitals accounting for 54.18%, 34.03%, and 11.79%, respectively, of the revenue from operations in Fiscal 2023.<\/p>\n

Objects of the Issue<\/h2>\n

The company intends to utilize the net proceeds from the issue towards the funding of the following objects:<\/p>\n

    \n
  1. Repayment\/pre-payment, in full or part, of borrowings availed from banks by the company and Material Subsidiary; and<\/li>\n
  2. General corporate purposes.<\/li>\n<\/ol>\n